Ambrx Biopharma Inc. (NYSE:AMAM – Get Rating) major shareholder Cormorant Asset Management, Lp acquired 562,121 shares of the company’s stock in a transaction dated Monday, April 17th. The stock was acquired at an average cost of $10.67 per share, for a total transaction of $5,997,831.07. Following the completion of the acquisition, the insider now directly owns 62,097,896 shares in the company, valued at $662,584,550.32. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Cormorant Asset Management, Lp also recently made the following trade(s):

* On Thursday, April 13th, Cormorant Asset Management, Lp bought 1,193,808 shares of Ambrx Biopharma stock. The shares were acquired at an average price of $9.16 per share, with a total value of $10,935,281.28.

* On Thursday, March 16th, Cormorant Asset Management, Lp purchased 500,000 shares of Ambrx Biopharma stock. The shares were bought at an average cost of $10.15 per share, for a total transaction of $5,075,000.00.

* On Tuesday, March 14th, Cormorant Asset Management, Lp acquired 250,000 shares of Ambrx Biopharma stock. The stock was bought at an average cost of $9.95 per share, with a total value of $2,487,500.00.

Shares of Ambrx Biopharma stock opened at $11.36 on Wednesday. The firm has a 50-day simple moving average of $7.42 and a two-hundred day simple moving average of $3.52. Ambrx Biopharma Inc. has a fifty-two week low of $0.38 and a fifty-two week high of $13.07.

Several institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC raised its position in  Ambrx Biopharma by 0.8% during the second quarter. FMR LLC now owns 3,857,679 shares of the company’s stock worth $10,223,000 after acquiring an additional 32,320 shares during the period.  Renaissance Technologies LLC increased its stake in shares of  Ambrx Biopharma by 91.5% during the first quarter. Renaissance Technologies LLC now owns 22,600 shares of the company’s stock worth $93,000 after purchasing an additional 10,800 shares in the last quarter.  Royal Bank of Canada acquired a new position in shares of  Ambrx Biopharma during the 3rd quarter worth about $46,000.  B. Riley Wealth Advisors Inc. acquired a new position in shares of  Ambrx Biopharma during the 4th quarter worth about $45,000.  Finally, Alpine Global Management LLC purchased a new position in  Ambrx Biopharma in the 4th quarter valued at about $106,000. Hedge funds and other institutional investors own  43.14% of the company’s stock.

Several analysts recently commented on the company. Robert W. Baird raised their target price on Ambrx Biopharma from $11.00 to $12.00 and gave the stock an “outperform” rating in a report on Wednesday, April 5th. The Goldman Sachs Group raised their price objective on shares of Ambrx Biopharma from $2.00 to $6.00 and gave the stock a “neutral” rating in a research note on Monday, February 27th.

Ambrx Biopharma Inc, a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer.

Receive News & Ratings for Ambrx Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambrx Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.